# Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Source: https://onco.cc/trials/nct05363280/  
OnCo record `nct05363280` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting.

## Summary

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment is a phase 2 interventional study registered as NCT05363280 by Advenchen Pharmaceuticals, LLC., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-12. Interventions recorded: AL8326 40 mg, AL8326 60 mg and AL8326 80 mg--stopped.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05363280
- Phase: 2
- Setting: A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment
- Sponsor: Advenchen Pharmaceuticals, LLC.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05363280: https://clinicaltrials.gov/study/NCT05363280

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/)

---
JSON: https://onco.cc/api/v1/entities/nct05363280.json